1. New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a modest effect (ACEIs) or no impact (  -blockers) on QoL Some therapies that improve QoL (eg, inotropic agents) do not improve survival

2.  = 2.4, P<0.001 Baseline M12 Baseline M12 55 70 75 60 65  6.7  4.3 KCCQ OSS Ekman I et al. Eur Heart J. 2011. Online August 29. Ivabradine (n=842) Placebo (n=839) Ivabradine improves Health-related quality of life

3. Incidence of CV death or HF hospitalization (%) Time (months) Score ≥75* Score 50-<75* Score <50* Patients having a better quality of life have less risk of cardiovascular events P<0.001 Ekman I et al. Eur Heart J. 2011. Online August 29. *KCCQ-OSS score in placebo group

4. P=<0.001 Higher HR reduction… greater quality of life with Ivabradine Ekman I et al. Eur Heart J. 2011. Online August 29.

5. Conclusions Heart rate slowing with ivabradine in patients with chronic systolic HF in sinus rhythm with HR ≥70 bpm 1.Improves survival or heart failure hospitalizations 2.Improves HQoL